Developer docs
API playgroundTry for free, no card

Search company profiles

Ceres Nanosciences

Full company profile

uuid0002e19

Namestring
Ceres Nanosciences
Legal namestring
Ceres Nanosciences, Inc.
Websiteurl
ceresnano.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Ceres Nanosciences is a privately held life-sciences company that develops and commercializes the Nanotrap particle technology platform — magnetic hydrogel particles engineered to capture and concentrate low-abundance analytes (pathogens, proteins, cell-free DNA, and extracellular vesicles) from complex biological and environmental samples. Founded in 2008 and headquartered in Manassas, Virginia, the company serves four primary use-case segments: wastewater and environmental surveillance (infectious disease monitoring for SARS-CoV-2, influenza, mpox, norovirus, etc.), proteomics and mass spectrometry (low-abundance protein enrichment for LC-MS/MS), liquid biopsy and cfDNA analysis (oncology and precision-medicine research), and clinical diagnostics. The technology is protected by an issued US, Canadian, European, and Japanese patent estate, has been published in Nature and other peer-reviewed journals, and is validated across matrices including wastewater, blood, urine, plasma, and dried blood spots.

The product portfolio is anchored by four core consumable lines — Nanotrap Microbiome Particles, Nanotrap PEAK (Protein Enrichment Affinity Kit), NEAT Liquid Biopsy Kit (including a Streck BCT variant), and Nanotrap Extracellular Vesicle Particles — supplemented by Enhancement Reagents, Buffers, the Nanotrap PRIME Extraction Kit, and the CeresNOW technical-support service. Products are sold research-use-only via direct, quote-based pricing (FOB Manassas), and the company operates a Centers of Excellence reference-site program that has grown to 16 active US wastewater surveillance sites with 5 additional sites in recruitment. Revenue mechanics are one-time consumable sales rather than subscriptions, with the customer mix dominated by public-health laboratories, academic proteomics cores, and clinical research accounts; strategic capital has historically come from NIH (RADx), CDC, the Bill & Melinda Gates Foundation, Virginia Catalyst, and venture investors Concord Ventures and GreyBird Ventures. With only 1–10 employees, the company relies on validated integrations with major OEM platforms (QIAGEN, Thermo Fisher, Promega, MACHEREY-NAGEL, Bio-Rad, Bruker, IDEXX, ZymoBIOMICS, New England Biolabs) to extend its commercial reach.

Short descriptiontext

Ceres Nanosciences is a Manassas, Virginia-based private life-sciences company that develops Nanotrap magnetic hydrogel particles for capturing and concentrating low-abundance pathogens, proteins, and cell-free DNA, serving academic, public-health, and clinical research laboratories in wastewater surveillance, proteomics, and liquid biopsy applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersManassas, United States
HQ citystring
Manassas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sample preparation reagents, magnetic hydrogel particles, wastewater surveillance kits, proteomics enrichment kits, liquid biopsy cfDNA kits
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAJABAI
Wastewater & Environmental Pathogen Surveillance
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code1 code
  • Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing3252
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Life Sciences Sample Preparation Reagents
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Nanotrap Consumable Products
TypeOne Time License
Description

Sale of Nanotrap magnetic hydrogel particle-based kits and reagents for research use. Products include Microbiome Particles, Enhancement Reagents, Buffers, PEAK kits, NEAT Liquid Biopsy Kits, and Extracellular Vesicle Particles. Sold in various sizes (e.g., 10mL, 30mL vials). Products ship FOB company facility.

ceresnano.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Research use only products - quote-based pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products for research use only, not for human or animal therapeutic or diagnostic use. Payment terms: 30 days from invoice date. Custom products available for specific analyte targets.

ceresnano.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Nanotrap
Description

Core magnetic hydrogel particle technology platform for capture and concentration of low-abundance analytes

ceresnano.com
+5 more records
Core offering1 text field

Ceres Nanosciences develops, manufactures, and sells consumable Nanotrap® magnetic hydrogel particle-based kits and reagents for research use. Its products capture and concentrate low-abundance pathogens, proteins, cell-free DNA, and extracellular vesicles from complex samples such as wastewater, blood, urine, and plasma without filtration, centrifugation, or bead-beating, and are compatible with manual and automated workflows including KingFisher, QIAGEN, Promega, and Thermo Fisher platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 2-10x higher recovery of microbes from wastewater compared to alternative methods
+7 more records
Product overview1 text field

Ceres Nanosciences offers a portfolio of products based on its core Nanotrap Particle Technology, a magnetic hydrogel platform for rapid capture and concentration of low-abundance analytes from complex samples. The product portfolio includes: Nanotrap Microbiome Particles for infectious disease and wastewater surveillance applications; Nanotrap Protein Enrichment Affinity Kit (PEAK) for proteomics workflows; NEAT Liquid Biopsy Kit for cell-free DNA and cancer biomarker detection; and Nanotrap Extracellular Vesicle Particles for EV isolation. These are supported by add-on enhancement reagents, buffers, and the CeresNOW technical support service. All products are compatible with both manual and automated workflows, including integration with KingFisher instruments and various extraction kits and PCR analysis systems.

Product and service8 records
1Nanotrap Microbiome Particles
CategoryInfectious Disease Sample Preparation
Description

Magnetic hydrogel particles designed for rapid capture and concentration of pathogens, bacteria, fungi, and parasites from complex biological and environmental samples including wastewater, blood, urine, and plasma. For research-use laboratories in public health, wastewater surveillance, and infectious disease workflows.

2Nanotrap Enhancement Reagents
CategoryInfectious Disease Sample Preparation
Description

Enhancement reagents (ER1, ER2, ER3) sold as a standalone consumable that improves pathogen capture and detection sensitivity by an additional 1-2 Ct values when used with Nanotrap Microbiome Particle workflows. For research-use laboratories in infectious disease and wastewater surveillance.

3Nanotrap Buffers
CategoryProteomics Sample Preparation
Description

Standalone buffer solutions including Nanotrap Buffer 2 and Nanotrap DBS Buffer for protein extraction from dried blood samples and integration with Nanotrap PEAK Discovery workflows. For proteomics and clinical sample preparation research labs.

4Nanotrap PRIME Extraction Kit
CategorySample Preparation Extraction
Description

Extraction kit for efficient sample preparation and enrichment in quantitative proteomics and infectious disease research applications.

5Nanotrap Protein Enrichment Affinity Kit (PEAK)
CategoryProteomics Sample Preparation
Description

Magnetic hydrogel-based protein enrichment kit that enriches low-abundance proteins and peptides from complex biofluids while depleting high-abundance interferents such as albumin and immunoglobulins, enabling 3-5x more protein identifications with median CVs less than 5%. For proteomics and mass spectrometry research labs running LC-MS/MS workflows.

6NEAT Liquid Biopsy Kit
CategoryLiquid Biopsy Sample Preparation
Description

Nanotrap Extraction Advanced Technology kit for liquid biopsy applications that isolates and concentrates cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) from plasma samples while minimizing genomic DNA contamination. Includes a Streck BCT variant for room-temperature blood collection tubes. For oncology, precision medicine, and translational research labs using digital PCR and NGS.

7Nanotrap Extracellular Vesicle Particles
CategoryExtracellular Vesicle Sample Preparation
Description

Magnetic hydrogel particles for capture and concentration of extracellular vesicles (EVs) and associated biomarkers from biofluids. For EV biomarker research and translational labs.

8CeresNOW Support
CategoryTechnical Support Service
Description

Expert technical support service providing assay optimization and workflow development assistance for customers using Nanotrap products, with lightning-fast response times.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with CDC's NWSS program for integration of Nanotrap-based wastewater surveillance into public health decision-making at local, state, and federal levels.

Strategic tierMajorTypeTechnology or Integration
Description

QIAGEN extraction kits (QIAamp Viral RNA Mini Kit, AllPrep PowerViral DNA/RNA Kit, MagAttract Viral RNA Kit) have validated protocols with Nanotrap particles. Products compatible with QIAGEN QIAcuity Digital PCR System.

Strategic tierMajorTypeTechnology or Integration
Description

Nanotrap protocols validated with Thermo Fisher MagMAX Microbiome Ultra Nucleic Acid Isolation Kit and KingFisher systems (Apex, Flex).

Strategic tierMajorTypeTechnology or Integration
Description

Nanotrap protocols validated with Promega Maxwell HT Environmental TNA Kit for automated and manual processing.

Strategic tierMajorTypeTechnology or Integration
Description

Co-hosted webinars on wastewater surveillance. Nanotrap protocols validated with NucleoMag DNA/RNA Water Extraction Kit.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Zymo Research is a privately held life sciences company specializing in nucleic acid purification and microbiome sample preparation, with product lines overlapping directly with Ceres's wastewater surveillance and microbiome capture applications. Their DNA/RNA extraction kits (including MagBead) compete with Nanotrap Microbiome Particles in the same customer workflow, and they are also listed as a validated integration partner for Ceres.

TypeDirect peer
Description

Seer is a publicly traded proteomics company (SEER on Nasdaq) that uses engineered nanoparticles for unbiased, deep-scale plasma proteomics, directly competing with Ceres's Nanotrap PEAK protein enrichment kit. Both companies apply functionalized nanoparticle technology to enable deep proteomic analysis from limited samples, making them the closest technology and application peer in the proteomics sample prep space.

TypeDirect peer
Description

Covaris develops adaptive focused acoustic (AFA) technology for sample preparation including nucleic acid extraction and shearing, serving liquid biopsy, genomics, and proteomics markets. Their disruptive sample preparation approach competes with Nanotrap particles in liquid biopsy and microbiome workflows, particularly for high-value clinical research applications.

TypeBroad incumbent
Description

Bio-Rad is a large life sciences incumbent whose ddPCR systems (QX200) and laboratory consumables serve the same molecular biology and clinical research customers as Ceres. Their magnetic bead-based sample prep reagents and integrated droplet digital PCR workflows overlap with Ceres's downstream analysis integrations, and they are a validated Ceres integration partner.

TypeBroad incumbent
Description

Thermo Fisher is the largest life sciences tools company globally, with KingFisher automated extraction systems and MagMAX nucleic acid isolation kits that compete directly with Nanotrap in microbiome, wastewater, and clinical research workflows. They are simultaneously a Ceres integration partner (KingFisher Apex/Flex validated protocols) and a potential competitor if they develop competing capture chemistries.

TypeBroad incumbent
Description

QIAGEN is a major sample preparation and molecular diagnostics company whose QIAamp Viral RNA Mini Kit, AllPrep PowerViral DNA/RNA Kit, and QIAcuity Digital PCR System serve the same wastewater surveillance and liquid biopsy customers as Ceres. They have validated protocols with Nanotrap particles but also offer end-to-end competing workflows.

TypeBroad incumbent
Description

Promega is a broad life sciences reagents and instruments company whose Maxwell HT Environmental TNA Kit and related automated extraction products serve the same wastewater and environmental surveillance customers as Ceres. They have validated Nanotrap workflows but also offer competing sample prep chemistries across multiple research applications.

TypeDirect peer
Description

MagBio Genomics specializes in magnetic bead-based nucleic acid extraction and sample preparation kits for clinical and research applications, with a focused product line that competes directly with Nanotrap Microbiome Particles and NEAT Liquid Biopsy Kit in cfDNA and viral RNA workflows. They are a smaller specialty peer serving overlapping customer segments.

TypeDirect peer
Description

Omega Bio-tek manufactures nucleic acid purification reagents and kits including magnetic bead-based products for clinical, research, and environmental sample types. Their products compete directly with Nanotrap in wastewater, microbiome, and liquid biopsy sample preparation workflows serving similar academic and public health lab customers.

TypeBroad incumbent
Description

Streck is a privately held company specializing in clinical and research lab products including the Cell-Free DNA BCT blood collection tubes that are validated for use with Ceres's NEAT Liquid Biopsy Kit. While Streck focuses on collection tubes and stabilization rather than analyte capture, they serve the same liquid biopsy customers and have complementary product positioning in the cfDNA workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ceres Nanosciences

Life Sciences Sample Preparation Reagentsceresnano.com

Ceres Nanosciences is a Manassas, Virginia-based private life-sciences company that develops Nanotrap magnetic hydrogel particles for capturing and concentrating low-abundance pathogens, proteins, and cell-free DNA, serving academic, public-health, and clinical research laboratories in wastewater surveillance, proteomics, and liquid biopsy applications.

What Ceres Nanosciences does

Ceres Nanosciences is a privately held life-sciences company that develops and commercializes the Nanotrap particle technology platform — magnetic hydrogel particles engineered to capture and concentrate low-abundance analytes (pathogens, proteins, cell-free DNA, and extracellular vesicles) from complex biological and environmental samples. Founded in 2008 and headquartered in Manassas, Virginia, the company serves four primary use-case segments: wastewater and environmental surveillance (infectious disease monitoring for SARS-CoV-2, influenza, mpox, norovirus, etc.), proteomics and mass spectrometry (low-abundance protein enrichment for LC-MS/MS), liquid biopsy and cfDNA analysis (oncology and precision-medicine research), and clinical diagnostics. The technology is protected by an issued US, Canadian, European, and Japanese patent estate, has been published in Nature and other peer-reviewed journals, and is validated across matrices including wastewater, blood, urine, plasma, and dried blood spots.

The product portfolio is anchored by four core consumable lines — Nanotrap Microbiome Particles, Nanotrap PEAK (Protein Enrichment Affinity Kit), NEAT Liquid Biopsy Kit (including a Streck BCT variant), and Nanotrap Extracellular Vesicle Particles — supplemented by Enhancement Reagents, Buffers, the Nanotrap PRIME Extraction Kit, and the CeresNOW technical-support service. Products are sold research-use-only via direct, quote-based pricing (FOB Manassas), and the company operates a Centers of Excellence reference-site program that has grown to 16 active US wastewater surveillance sites with 5 additional sites in recruitment. Revenue mechanics are one-time consumable sales rather than subscriptions, with the customer mix dominated by public-health laboratories, academic proteomics cores, and clinical research accounts; strategic capital has historically come from NIH (RADx), CDC, the Bill & Melinda Gates Foundation, Virginia Catalyst, and venture investors Concord Ventures and GreyBird Ventures. With only 1–10 employees, the company relies on validated integrations with major OEM platforms (QIAGEN, Thermo Fisher, Promega, MACHEREY-NAGEL, Bio-Rad, Bruker, IDEXX, ZymoBIOMICS, New England Biolabs) to extend its commercial reach.

Ceres Nanosciences firmographics

Firmographics
Name
Ceres Nanosciences
Legal name
Ceres Nanosciences, Inc.
Website
https://ceresnano.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Ceres Nanosciences is a Manassas, Virginia-based private life-sciences company that develops Nanotrap magnetic hydrogel particles for capturing and concentrating low-abundance pathogens, proteins, and cell-free DNA, serving academic, public-health, and clinical research laboratories in wastewater surveillance, proteomics, and liquid biopsy applications.
Ownership category
akta.pro rank

Ceres Nanosciences industry classification

Industry
Product category
Life Sciences Sample Preparation Reagents
NAICS
Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAJABAI
Wastewater & Environmental Pathogen Surveillance
Healthcare & Life Sciences/Public Health, Government & Regulators/Disease Surveillance, Epidemiology & Outbreak Response
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Sample preparation reagents
  • Magnetic hydrogel particles
  • Wastewater surveillance kits
  • Proteomics enrichment kits
  • Liquid biopsy cfDNA kits

Where Ceres Nanosciences is headquartered

Location

Headquarters

HQ city
Manassas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ceres Nanosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Nanotrap Consumable Products: Sale of Nanotrap magnetic hydrogel particle-based kits and reagents for research use. Products include Microbiome Particles, Enhancement Reagents, Buffers, PEAK kits, NEAT Liquid Biopsy Kits, and Extracellular Vesicle Particles. Sold in various sizes (e.g., 10mL, 30mL vials). Products ship FOB company facility.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goResearch use only products - quote-based pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Ceres Nanosciences product offering

Product offering

Core offering

Ceres Nanosciences develops, manufactures, and sells consumable Nanotrap® magnetic hydrogel particle-based kits and reagents for research use. Its products capture and concentrate low-abundance pathogens, proteins, cell-free DNA, and extracellular vesicles from complex samples such as wastewater, blood, urine, and plasma without filtration, centrifugation, or bead-beating, and are compatible with manual and automated workflows including KingFisher, QIAGEN, Promega, and Thermo Fisher platforms.

Product overview

Ceres Nanosciences offers a portfolio of products based on its core Nanotrap Particle Technology, a magnetic hydrogel platform for rapid capture and concentration of low-abundance analytes from complex samples. The product portfolio includes: Nanotrap Microbiome Particles for infectious disease and wastewater surveillance applications; Nanotrap Protein Enrichment Affinity Kit (PEAK) for proteomics workflows; NEAT Liquid Biopsy Kit for cell-free DNA and cancer biomarker detection; and Nanotrap Extracellular Vesicle Particles for EV isolation. These are supported by add-on enhancement reagents, buffers, and the CeresNOW technical support service. All products are compatible with both manual and automated workflows, including integration with KingFisher instruments and various extraction kits and PCR analysis systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Nanotrap: Core magnetic hydrogel particle technology platform for capture and concentration of low-abundance analytes
  • Nanotrap Enhancement Reagents
  • Nanotrap PRIME Extraction Kit
  • Nanotrap PEAK
  • NEAT Liquid Biopsy Kit
  • CeresNOW

Products and services

  • Nanotrap Microbiome Particles Magnetic hydrogel particles designed for rapid capture and concentration of pathogens, bacteria, fungi, and parasites from complex biological and environmental samples including wastewater, blood, urine, and plasma. For research-use laboratories in public health, wastewater surveillance, and infectious disease workflows.
  • Nanotrap Enhancement Reagents Enhancement reagents (ER1, ER2, ER3) sold as a standalone consumable that improves pathogen capture and detection sensitivity by an additional 1-2 Ct values when used with Nanotrap Microbiome Particle workflows. For research-use laboratories in infectious disease and wastewater surveillance.
  • Nanotrap Buffers Standalone buffer solutions including Nanotrap Buffer 2 and Nanotrap DBS Buffer for protein extraction from dried blood samples and integration with Nanotrap PEAK Discovery workflows. For proteomics and clinical sample preparation research labs.
  • Nanotrap PRIME Extraction Kit Extraction kit for efficient sample preparation and enrichment in quantitative proteomics and infectious disease research applications.
  • Nanotrap Protein Enrichment Affinity Kit (PEAK) Magnetic hydrogel-based protein enrichment kit that enriches low-abundance proteins and peptides from complex biofluids while depleting high-abundance interferents such as albumin and immunoglobulins, enabling 3-5x more protein identifications with median CVs less than 5%. For proteomics and mass spectrometry research labs running LC-MS/MS workflows.
  • NEAT Liquid Biopsy Kit Nanotrap Extraction Advanced Technology kit for liquid biopsy applications that isolates and concentrates cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) from plasma samples while minimizing genomic DNA contamination. Includes a Streck BCT variant for room-temperature blood collection tubes. For oncology, precision medicine, and translational research labs using digital PCR and NGS.
  • Nanotrap Extracellular Vesicle Particles Magnetic hydrogel particles for capture and concentration of extracellular vesicles (EVs) and associated biomarkers from biofluids. For EV biomarker research and translational labs.
  • CeresNOW Support Expert technical support service providing assay optimization and workflow development assistance for customers using Nanotrap products, with lightning-fast response times.

Quantifiable outcome

  • 2-10x higher recovery of microbes from wastewater compared to alternative methods
  • +7 more outcomes

Companies that use Ceres Nanosciences

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Ceres Nanosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Ceres Nanosciences partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • CDC National Wastewater Surveillance SystemcoreStrategic or Co-development PartnerCollaboration with CDC's NWSS program for integration of Nanotrap-based wastewater surveillance into public health decision-making at local, state, and federal levels.
  • QIAGENmajorTechnology or IntegrationQIAGEN extraction kits (QIAamp Viral RNA Mini Kit, AllPrep PowerViral DNA/RNA Kit, MagAttract Viral RNA Kit) have validated protocols with Nanotrap particles. Products compatible with QIAGEN QIAcuity Digital PCR System.
  • Thermo Fisher ScientificmajorTechnology or IntegrationNanotrap protocols validated with Thermo Fisher MagMAX Microbiome Ultra Nucleic Acid Isolation Kit and KingFisher systems (Apex, Flex).
  • PromegamajorTechnology or IntegrationNanotrap protocols validated with Promega Maxwell HT Environmental TNA Kit for automated and manual processing.
  • MACHEREY-NAGELmajorTechnology or IntegrationCo-hosted webinars on wastewater surveillance. Nanotrap protocols validated with NucleoMag DNA/RNA Water Extraction Kit.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Ceres Nanosciences competitors and assessment

Company assessment

Direct peers

  • Zymo Research: Zymo Research is a privately held life sciences company specializing in nucleic acid purification and microbiome sample preparation, with product lines overlapping directly with Ceres's wastewater surveillance and microbiome capture applications. Their DNA/RNA extraction kits (including MagBead) compete with Nanotrap Microbiome Particles in the same customer workflow, and they are also listed as a validated integration partner for Ceres.
  • Seer: Seer is a publicly traded proteomics company (SEER on Nasdaq) that uses engineered nanoparticles for unbiased, deep-scale plasma proteomics, directly competing with Ceres's Nanotrap PEAK protein enrichment kit. Both companies apply functionalized nanoparticle technology to enable deep proteomic analysis from limited samples, making them the closest technology and application peer in the proteomics sample prep space.
  • Covaris: Covaris develops adaptive focused acoustic (AFA) technology for sample preparation including nucleic acid extraction and shearing, serving liquid biopsy, genomics, and proteomics markets. Their disruptive sample preparation approach competes with Nanotrap particles in liquid biopsy and microbiome workflows, particularly for high-value clinical research applications.
  • MagBio Genomics: MagBio Genomics specializes in magnetic bead-based nucleic acid extraction and sample preparation kits for clinical and research applications, with a focused product line that competes directly with Nanotrap Microbiome Particles and NEAT Liquid Biopsy Kit in cfDNA and viral RNA workflows. They are a smaller specialty peer serving overlapping customer segments.
  • Omega Bio-tek: Omega Bio-tek manufactures nucleic acid purification reagents and kits including magnetic bead-based products for clinical, research, and environmental sample types. Their products compete directly with Nanotrap in wastewater, microbiome, and liquid biopsy sample preparation workflows serving similar academic and public health lab customers.

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad is a large life sciences incumbent whose ddPCR systems (QX200) and laboratory consumables serve the same molecular biology and clinical research customers as Ceres. Their magnetic bead-based sample prep reagents and integrated droplet digital PCR workflows overlap with Ceres's downstream analysis integrations, and they are a validated Ceres integration partner.
  • Thermo Fisher Scientific: Thermo Fisher is the largest life sciences tools company globally, with KingFisher automated extraction systems and MagMAX nucleic acid isolation kits that compete directly with Nanotrap in microbiome, wastewater, and clinical research workflows. They are simultaneously a Ceres integration partner (KingFisher Apex/Flex validated protocols) and a potential competitor if they develop competing capture chemistries.
  • QIAGEN: QIAGEN is a major sample preparation and molecular diagnostics company whose QIAamp Viral RNA Mini Kit, AllPrep PowerViral DNA/RNA Kit, and QIAcuity Digital PCR System serve the same wastewater surveillance and liquid biopsy customers as Ceres. They have validated protocols with Nanotrap particles but also offer end-to-end competing workflows.
  • Promega: Promega is a broad life sciences reagents and instruments company whose Maxwell HT Environmental TNA Kit and related automated extraction products serve the same wastewater and environmental surveillance customers as Ceres. They have validated Nanotrap workflows but also offer competing sample prep chemistries across multiple research applications.
  • Streck: Streck is a privately held company specializing in clinical and research lab products including the Cell-Free DNA BCT blood collection tubes that are validated for use with Ceres's NEAT Liquid Biopsy Kit. While Streck focuses on collection tubes and stabilization rather than analyte capture, they serve the same liquid biopsy customers and have complementary product positioning in the cfDNA workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Ceres Nanosciences social profiles

Digital presence

Ceres Nanosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ceres Nanosciences leadership team

Management profile

Number of profiles

Profiles5 records

Ceres Nanosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ceres Nanosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceres Nanosciences

What does Ceres Nanosciences do?

Ceres Nanosciences develops, manufactures, and sells consumable Nanotrap® magnetic hydrogel particle-based kits and reagents for research use. Its products capture and concentrate low-abundance pathogens, proteins, cell-free DNA, and extracellular vesicles from complex samples such as wastewater, blood, urine, and plasma without filtration, centrifugation, or bead-beating, and are compatible with manual and automated workflows including KingFisher, QIAGEN, Promega, and Thermo Fisher platforms.

Is Ceres Nanosciences a public or private company?

Ceres Nanosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ceres Nanosciences founded?

Ceres Nanosciences was founded in 2008. It employs 11 to 50 people.

Where is Ceres Nanosciences based?

Ceres Nanosciences is headquartered in Manassas, United States, in the North America region.

How does Ceres Nanosciences make money?

One revenue line is on record: nanotrap Consumable Products.

Who are Ceres Nanosciences's main competitors?

Direct peers on record are Zymo Research, Seer, Covaris, MagBio Genomics and Omega Bio-tek. Broad incumbents are Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN, Promega and Streck.

Does Ceres Nanosciences have an API?

No public API is recorded for Ceres Nanosciences.

What industry is Ceres Nanosciences in?

Ceres Nanosciences's product category is Life Sciences Sample Preparation Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAJABAI, Wastewater & Environmental Pathogen Surveillance. Its NAICS code is 3252 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GmuMason Start-Ups – The Institute for Biohealth InnovationThe Institute for Biohealth Innovation at Mason lists several start-ups, including AexeRNA Therapeutics, Ceres Nanosciences, and NIRView Biosciences, among others, as part of its portfolio. These companies are engaged in various biotech activities such as mRNA therapeutics, nanofabrication, medical imaging, and precision medicine. The article serves as a directory of these affiliated entities rather than reporting on specific operational events.GmuGeorge Mason interns make a difference at biotech start-upsGeorge Mason University students completed internships at biotech start-ups in the university's Innovation District, gaining industry experience through programs linking graduate research with commercial applications. Participants worked at companies including Ceres Nanosciences, Virongy Biosciences, and Tracked Biotechnologies LLC, engaging in activities such as clinical trial support, diagnostic development, and AI tool creation.American City Business JournalsWhat NIH cuts would mean for D.C.-area biotech companies, universitiesThe NIH announced a 15% cap on indirect cost rates for grants, a move the agency claims would save over $4 billion annually but which industry and academic leaders warn could cripple research operations. A federal judge has temporarily blocked the policy following lawsuits from multiple states and higher-education institutions, including Johns Hopkins University and George Washington University. Local biotech firms such as miRecule Inc. and Ceres Nanosciences Inc. express concern that the uncertainty jeopardizes secured funding vital for early-stage drug development and manufacturing.PR NewswireCeres Nanosciences and Ginkgo Bioworks Partner to Bring Pathogen Monitoring Capabilities to Labs Around the WorldCeres Nanosciences and Ginkgo Bioworks announced a partnership to expand pathogen monitoring capabilities, including wastewater testing, to laboratories worldwide. The collaboration combines Ceres' Nanotrap technology—which was developed with NIH RADx support and provides sensitive pathogen detection methods—with Concentric by Ginkgo's global biosecurity network and data infrastructure. The partners have already established operational labs in the Middle East and Africa as part of this capacity-building initiative.SecSEC FORM DCeres Nanosciences, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt offering of securities under Rule 506(c). The filing indicates a minimum investment threshold of $5,000,000 USD for accredited investors, with the first sale occurring on September 1, 2022. This regulatory submission formalizes the company's private capital raise activities in the United States.PR NewswireCeres Nanosciences Receives $8.2M NIH Award to Improve Wastewater-Based COVID-19 SurveillanceCeres Nanosciences has been awarded an $8.2 million contract from the NIH Rapid Acceleration of Diagnostics (RADx) Initiative to develop and implement wastewater-based COVID-19 surveillance systems using the company's Nanotrap® Magnetic Virus Particles technology. The surveillance framework will be developed in partnership with Emory University researchers in the metro-Atlanta area, with a focus on underserved and vulnerable populations such as correctional facilities, low-income neighborhoods, and long-term care facilities. The award builds on a previous $6.57 million RADx grant and will establish a network of centers of excellence for high-throughput wastewater surveillance nationwide.Medical Tech OutlookInvesting in Precision DiagnosticsGreyBird Ventures, a medical diagnostics investment firm, outlines its thesis on the critical need for precision diagnostics to reduce healthcare costs and improve outcomes in the United States. The article highlights specific investments in GNA Biosolutions and Ceres Nanosciences to address testing needs during the COVID-19 pandemic.YahooA technology backed by Bill Gates may revolutionize diagnostics for Lyme diseaseCeres Nanosciences developed a urine-based nanotrap test for Lyme disease, backed by the Bill and Melinda Gates Foundation with over $1 million. The company plans a $9 million Series A to fund FDA approval. Early detection could improve treatment outcomes.American City Business JournalsCeres Nanosciences: Making easier, more effective disease testsCeres Nanosciences developed a nanotrap antigen test that detects infectious agents directly, improving sensitivity by 100 times or more. The test uses urine samples and was first applied to Lyme disease, with over $4 million in funding. The company aims to expand applications to other diseases and develop noninvasive preventative screenings.